Docoh
Loading...

VRNA Verona Pharma

Employees

Data from SEC filings
Employee count

ESG framework mentions

In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions

ESG term mentions

In last year of SEC filings

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM


On April 27, 2021, Verona Pharma plc (the “Company”) held its 2021 Annual General Meeting of Shareholders (the “AGM”), and all resolutions were passed as proposed. Of the ordinary shares entitled to vote, there were 438,077,633 ordinary shares represented in person or by proxy at the AGM. The matters voted upon at the AGM, all of which were described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on March 19, 2021, and the final results of such voting are set forth below. Proxy forms which gave a person designated by the Company discretion have been included in the “For” total. In accordance with the terms of the deposit agreement by and among the Company, Citibank, N.A., as depositary, and holders and beneficial owners of American Depositary Shares (“ADSs”) issued thereunder, dated as of May 2, 2017, holders of ADSs as the ADS record date who did not provide the depositary bank with voting instructions on or before the voting cut-off time for ADS holders were deemed to have instructed the depositary bank to give a discretionary proxy to a person designated by the Company to vote the underlying ordinary shares at the AGM and the voting results below reflect that. A “vote withheld” is not a vote in law and votes withheld had no effect on the proposals. Votes withheld were counted as present and entitled to vote for purposes of determining a quorum.

Proposal 1. To re-elect David Ebsworth, Ph.D. as a Director of the Company.



FORAGAINSTWITHHELDBROKER NON-VOTES
437,364,35719,404693,872


Proposal 2. To re-elect Martin Edwards, M.D. as a Director of the Company.



FORAGAINSTWITHHELDBROKER NON-VOTES
438,029,80120,50427,328


Proposal 3. To re-elect Sven Anders Ullman, M.D., Ph.D. as a Director of the Company.



FORAGAINSTWITHHELDBROKER NON-VOTES
438,031,22519,08027,328


Proposal 4. To re-elect Lisa Deschamps as a Director of the Company.

FORAGAINSTWITHHELDBROKER NON-VOTES
437,987,65362,65227,328


Proposal 5. To receive and adopt the U.K. statutory annual accounts and Directors’ report for the year ended December 31, 2020 and the report of the auditors thereon.

FORAGAINSTWITHHELDBROKER NON-VOTES
438,049,23314,03214,368


Proposal 6. To receive and approve, as a non-binding advisory resolution, the U.K. statutory Directors’ Remuneration Report for the year ended December 31, 2020.

FORAGAINSTWITHHELDBROKER NON-VOTES
437,440,863624,25012,520


Proposal 7. To receive and approve the U.K. Directors’ Remuneration Policy.



FORAGAINSTWITHHELDBROKER NON-VOTES
437,393,559658,75425,320


Proposal 8. To re-appoint PricewaterhouseCoopers LLP as the Company’s auditors, to hold office until the conclusion of the next annual general meeting of shareholders.



FORAGAINSTWITHHELDBROKER NON-VOTES
438,048,05919,27010,304


Proposal 9. To authorize the Audit and Risk Committee to determine the auditors’ remuneration for the year ending December 31, 2021.



FORAGAINSTWITHHELDBROKER NON-VOTES
438,030,61327,78019,240


Proposal 10. To authorize the Board of Directors to exercise all the powers of the Company to allot shares in the Company or grant rights to subscribe for or to convert any security into shares in the Company up to an aggregate nominal amount of £24,415,222.30.



FORAGAINSTWITHHELDBROKER NON-VOTES
397,293,90140,753,25230,480


Proposal 11. To authorize the Board of Directors to allot equity securities for cash and/or to sell ordinary shares held by the Company as treasury shares for cash as if section 561(1) of the U.K. Companies Act 2006 does not apply to any such allotment.



FORAGAINSTWITHHELDBROKER NON-VOTES
397,273,90940,756,45247,272


Based on the foregoing votes, the shareholders re-elected each of David Ebsworth, Ph.D., Martin Edwards, M.D., Sven Anders Ullman, M.D., Ph.D. and Lisa Deschamps as directors, and approved Proposals 5, 6, 7, 8, 9, 10 and 11.